University of Washington, Seattle, USA.
Clin Infect Dis. 2010 Mar 1;50(5):787-91. doi: 10.1086/650539.
In AIDS Clinical Trials Group A5095, 9% of participants who experienced an adverse event related to efavirenz substituted nevirapine. Most adverse events resolved; 15 participants ultimately discontinued nevirapine therapy. Grade 3/4 hepatotoxicity was observed in 14% of individuals who substituted nevirapine, compared with 6% who continued efavirenz therapy. Substitution of nevirapine because of efavirenz toxicity was generally safe and efficacious. Clinical trials registration. NCT00013520 .
在 AIDS 临床试验组 A5095 中，9%经历与依非韦伦相关的不良事件的参与者改用奈韦拉平。大多数不良事件得到解决；15 名参与者最终停止奈韦拉平治疗。与继续接受依非韦伦治疗的 6%相比，改用奈韦拉平的个体中观察到 14%的 3/4 级肝毒性。由于依非韦伦毒性而改用奈韦拉平通常是安全有效的。临床试验注册。NCT00013520。
